<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="166406">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01798498</url>
  </required_header>
  <id_info>
    <org_study_id>PVN1</org_study_id>
    <nct_id>NCT01798498</nct_id>
  </id_info>
  <brief_title>Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds</brief_title>
  <official_title>Open-label Uncontrolled, Multicenter Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croma-Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FGK Clinical Research GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Croma-Pharma GmbH</source>
  <oversight_info>
    <authority>Austria: Austrian Medicines and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this clinical trial is to evaluate the efficacy and safety of Princess® VOLUME
      for the correction of nasolabial folds.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Modified Fitzpatrick Wrinkle Scale (MFWS) from Day 0 to Day 180</measure>
    <time_frame>Day 180</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Modified Fitzpatrick Wrinkle Scale (MFWS) from Day 0 to Days 30, 90, and 270</measure>
    <time_frame>Days 30, 90, and 270</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of at least 0.5 on the Modified Fitzpatrick Wrinkle Scale (MFWS)</measure>
    <time_frame>Days 30, 90, 180 and Day 270</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percentage of subjects with an improvement of at least 0.5 on the MFWS at Days 30, 90, 180 and Day 270</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject satisfaction</measure>
    <time_frame>Days 30, 90, 180, and 270</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subject satisfaction at Days 30, 90, 180, and 270</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Aesthetic Improvement</measure>
    <time_frame>Days 30, 90, 180, and 270</time_frame>
    <safety_issue>No</safety_issue>
    <description>Global Aesthetic Improvement Scale (GAIS) at Days 30, 90, 180, and 270</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Days 0, 14, 30, 90, 180, 270</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Princess® VOLUME</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of Princess® VOLUME into the deep dermis or subcutis of both nasolabial folds.
A touch-up treatment may be performed at Day 14 if correction is not complete after the first injection.
The injected volumes will be estimated by the investigator and depend on the depth of the nasolabial folds</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Princess® VOLUME</intervention_name>
    <arm_group_label>Princess® VOLUME</arm_group_label>
    <other_name>highly cross-linked, viscoelastic hyaluronic acid injectable gel implant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Male or female subjects between 30 years and 65 years

          -  Wrinkle score of at least 2 according to the Modified Fitzpatrick Wrinkle Scale
             (MFWS)

        Major Exclusion Criteria:

          -  For females: pregnancy, lactating, planned pregnancy or unwilling to use
             contraceptives

          -  History of allergic reaction to hyaluronic acid products

          -  Facial surgery or implantation of dermal fillers in the nasolabial region within the
             last 24 months

          -  Skin of the nasolabial region affected by cosmetic treatments (e.g. laser therapy
             within the last 12 months, chemical peeling within the last 3 months, dermabrasion
             within the last 12 months, botulinum toxin within the last 12 months )

          -  Connective tissue diseases

          -  Diabetes mellitus or uncontrolled systemic diseases

          -  Known human immune deficiency virus-positive individuals

          -  Presence of silicone implant or another non-absorbable substance (permanent fillers)
             in the area of product application

          -  Cutaneous lesions in the evaluated area

          -  Tendency to keloid formation and/or hypertrophic scars

          -  Autoimmune disease

          -  History of allergies against cosmetic filling products and re-current herpes simplex

          -  History of immune system degradation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisy Kopera, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Dermatology and Gerontology, Medical University Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ordination</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 22, 2013</lastchanged_date>
  <firstreceived_date>February 22, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
